Serum indomethacin concentrations after intravenous administration to preterm infants with patent ductus arteriosus. 1981

S Petersen, and N C Christensen, and K Møller Jensen, and E Ryssing

Six preterm infants with PDA received 14 treatments with indomethacin 0.2 mg/kg intravenously. Auscultatory and echocardiographic assessment indicated closure of the duct in 2, partial closure in 2, and no effect in 2 infants. The mean serum concentration of indomethacin was: 15 min after the first injection 1 314 ng/ml, after 1 hour 970 ng/ml, after 6 hours 718 ng/ml, and after 24 hours 388 ng/ml. The mean half-life of indomethacin in the serum was 20 hours (range 9-50 hours). Side effects in all infants were hyponatraemia, decreased urinary output, decreased urinary sodium excretion, and weight gain. One infant had transient thrombocytopenia and gastrointestinal haemorrhage. By intravenous administration of indomethacin in a dose of 0.2 mg/kg to preterm infants a sufficiently high serum concentration is obtained shortly after the injection. To maintain a high serum concentration for a longer period it is recommended to give a second dose of 0.2 mg/kg after 6 hours and if necessary a third dose of 0.1 mg/kg 24 hours after the first dose.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007235 Infant, Premature, Diseases Diseases that occur in PREMATURE INFANTS.
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D004374 Ductus Arteriosus, Patent A congenital heart defect characterized by the persistent opening of fetal DUCTUS ARTERIOSUS that connects the PULMONARY ARTERY to the descending aorta (AORTA, DESCENDING) allowing unoxygenated blood to bypass the lung and flow to the PLACENTA. Normally, the ductus is closed shortly after birth. Patent Ductus Arteriosus Familial,Patency of the Ductus Arteriosus,Patent Ductus Arteriosus
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Petersen, and N C Christensen, and K Møller Jensen, and E Ryssing
December 1991, Journal of paediatrics and child health,
S Petersen, and N C Christensen, and K Møller Jensen, and E Ryssing
January 2003, The Cochrane database of systematic reviews,
S Petersen, and N C Christensen, and K Møller Jensen, and E Ryssing
January 2021, The Cochrane database of systematic reviews,
S Petersen, and N C Christensen, and K Møller Jensen, and E Ryssing
May 2009, Acta paediatrica (Oslo, Norway : 1992),
S Petersen, and N C Christensen, and K Møller Jensen, and E Ryssing
June 1984, Archives of disease in childhood,
S Petersen, and N C Christensen, and K Møller Jensen, and E Ryssing
March 1982, European journal of pediatrics,
S Petersen, and N C Christensen, and K Møller Jensen, and E Ryssing
September 1988, BMJ (Clinical research ed.),
S Petersen, and N C Christensen, and K Møller Jensen, and E Ryssing
January 1992, Annals of tropical paediatrics,
S Petersen, and N C Christensen, and K Møller Jensen, and E Ryssing
August 2003, The Journal of pediatrics,
S Petersen, and N C Christensen, and K Møller Jensen, and E Ryssing
August 1980, The Medical journal of Australia,
Copied contents to your clipboard!